PRINCETON, N.J., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (“Sonnet” or the “Company”) (NASDAQ: SONN), a biopharmaceutical company developing innovative targeted ...
Sonnet BioTherapeutics (NASDAQ:SONN) will effect a 1-for-22 reverse stock split of its outstanding common stock, the company said Thursday. The reverse stock split will be effective as of the ...
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) shares are trading lower by 19.9% to 72 cents Wednesday afternoon after the company announced a 1-for-8 reverse stock split. What Else: Sonnet ...
Sonnet BioTherapeutics reports positive Phase 1 trial results for SON-1010 with ongoing studies for ovarian and soft-tissue cancers. Sonnet BioTherapeutics Holdings, Inc. has announced the completion ...
PRINCETON, NJ, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, ...
PRINCETON, NJ / ACCESSWIRE / April 13, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that dosing has ...
PRINCETON, N.J. - Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: NASDAQ:SONN), a biopharmaceutical company specializing in the development of targeted biologic drugs, announced it will implement a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results